Skip to main navigation
Skip to search
Skip to main content
UNT Health Home
Search content at UNT Health
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Inhibition of type a GABA receptors by L-type calcium channel blockers
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Inhibition of type a GABA receptors by L-type calcium channel blockers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
GABAA Receptor (GABAAR)
100%
L-type Calcium Channel Blocker
100%
Nitrendipine
100%
IC50
27%
Picrotoxin
27%
Dihydropyridine
18%
Site of Action
18%
Channel Blocker
18%
Nifedipine
18%
Zn++
18%
Binding Site
9%
Recombinant
9%
Inhibitory Effect
9%
Methyl
9%
Recombinant Human
9%
Inhibition Mechanism
9%
Modulatory
9%
Minimal Impact
9%
Stimulatory Effect
9%
Non-competitive
9%
Pharmacological Mechanism
9%
GABA Current
9%
Two-species
9%
Brain Slice
9%
L-type
9%
Transmembrane Voltage
9%
Channel Gating
9%
γ-butyrolactone
9%
Isopropyl
9%
Benzodiazepine Site
9%
GABAA
9%
Flumazenil
9%
Current Amplitude
9%
Human Embryonic Kidney 293 Cells
9%
Central Effects
9%
Verapamil
9%
Benzodiazepine Antagonist
9%
Decay Rate
9%
Ca++
9%
Current Decay
9%
Phenylalkylamine
9%
Initial Current
9%
Pharmacology, Toxicology and Pharmaceutical Science
4 Aminobutyric Acid Receptor
100%
Calcium Channel Blocker
100%
Nitrendipine
100%
Receptor
72%
4 Aminobutyric Acid
45%
IC50
27%
Picrotoxin
27%
Nifedipine
18%
Channel Blocker
18%
Zinc Ion
18%
Dihydropyridine Derivative
18%
Calcium Ion
9%
Binding Site
9%
Benzodiazepine
9%
Butyrolactone
9%
Flumazenil
9%
Verapamil
9%
Benzodiazepine Receptor Blocking Agent
9%
Phenylalkylamine
9%